OtologicPharmaceutics
Therapeutic Solutions for Hearing Health
Latest Press & Media
2020 – 2021 Updates from Otologic Pharaceutics
Articles about us: Oblato Acquires Rights to Hearing Loss Drug (https://hearingreview.com/inside-hearing/research/hei)Bringing Back Silence (https://houghear.org/bringing-back-silence/) Noteworthy News: Our President, Dr. Elaine Hamm, was an invited speaker to the...
Our mission
Otologic Pharmaceutics, Inc. (OPI) is a company committed to developing treatments for acute and chronic hearing loss to reduce the incidence and severity of permanent hearing disorders.
Our mission is to treat hearing loss.
Otologic Pharmaceutics, Inc. (OPI) is a company committed to developing treatments for acute and chronic hearing loss to reduce the incidence and severity of permanent hearing disorders.
OPI’s program NHPN-1010, an oral medication to treat acute hearing loss, has successfully completed a Phase I clinical trial. Initial research focuses on NHPN-1010 as a treatment for Noise Induced Hearing Loss. OPI’s program OPI-001, an innovative treatment for acute and chronic hearing loss through the regeneration of sensory hair cells, has been awarded a Congressionally Directed Medical Research Programs grant from the Department of Defense to fund further preclinical research and development.
Contact us
Call Us
Email Us
ehamm@ascendbioventures.com
Our Location
840 Research Parkway
Suite 250
Oklahoma City, OK 73104